Reza Pahlavan-Gharebaba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Reza Pahlavan-Gharebaba has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Ostadrahimi
Nutrition Research Center Tabriz University of Medical Sciences Tabriz Iran
1 shared publication - Majid Mobasseri
Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication - Mohamad Reza Ashoori
Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine , Tabriz University of Medical Sciences , Tabriz , Iran
1 shared publication - Mohammad Rahmati
Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication - Nosratollah Zarghami
Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication - Salar Bakhtiyari
Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, USA
1 shared publication
Latest Publications
- 28 December 2018
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 44 (5) , 667-675
Apelin-13 serum levels in type 2 diabetic obese women: possible relations with microRNAs-107 and 375
Objective: Apelin, an adipocytokine, is up-regulated by insulin and suppresses pancreatic insulin secretion. One of the key microRNAs in insulin resistance caused by obesity, is microRNA-107. MicroRNA-375 is expressed in the pancreatic islet cells. We aimed to explore apelin-13 and microRNA-107 and 375 in obese women with type 2 diabetes (T2D). Materials and Methods: Fifty obese women with newly diagnosed T2D and 50 non-diabetic obese women, as controls, were selected. Quantitative PCR and ELISA were used to measure the expression of microRNA-107 and 375 and Apelin-13 concentration, respectively. The role of apelin-13 was investigated in an in vitro model. Apoptosis was evaluated by flow cytometry. Results: Apelin-13 levels in diabetics were significantly more than controls (p=0.012). The expressions of microRNA-107 and 375 of diabetic group were increased, in comparison to the control group. There was no correlation between apelin-13 and microRNA-107 and 375 in diabetic and control groups. Significant correlations between apelin-13 and serotonin (p<0.001) and estimated average glucose (p<0.02) and insulin (p<0.03) were only observed in the diabetic group. Conclusion: Serum levels of apelin-13 and circulating microRNA-107 and 375 could be used as biomarkers for diabetes, particularly in obese subjects. However, more study is needed in this field.
- 28 December 2018
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 44 (5) , 667-675
Apelin-13 serum levels in type 2 diabetic obese women: possible relations with microRNAs-107 and 375
Objective: Apelin, an adipocytokine, is up-regulated by insulin and suppresses pancreatic insulin secretion. One of the key microRNAs in insulin resistance caused by obesity, is microRNA-107. MicroRNA-375 is expressed in the pancreatic islet cells. We aimed to explore apelin-13 and microRNA-107 and 375 in obese women with type 2 diabetes (T2D). Materials and Methods: Fifty obese women with newly diagnosed T2D and 50 non-diabetic obese women, as controls, were selected. Quantitative PCR and ELISA were used to measure the expression of microRNA-107 and 375 and Apelin-13 concentration, respectively. The role of apelin-13 was investigated in an in vitro model. Apoptosis was evaluated by flow cytometry. Results: Apelin-13 levels in diabetics were significantly more than controls (p=0.012). The expressions of microRNA-107 and 375 of diabetic group were increased, in comparison to the control group. There was no correlation between apelin-13 and microRNA-107 and 375 in diabetic and control groups. Significant correlations between apelin-13 and serotonin (p<0.001) and estimated average glucose (p<0.02) and insulin (p<0.03) were only observed in the diabetic group. Conclusion: Serum levels of apelin-13 and circulating microRNA-107 and 375 could be used as biomarkers for diabetes, particularly in obese subjects. However, more study is needed in this field.